Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071241 | 0.81 | MEN1 (0.42) | MEN1KMT2AMAPK1CYP2C9ALDH1A1 | |
| SCHEMBL19116604 | 0.77 | — | — | |
| SCHEMBL19381600 | 0.77 | PKM (0.45) | MEN1KMT2AFAAHMAPK1CYP2C9 | |
| SCHEMBL155431 | 0.76 | — | — | |
| SCHEMBL3058558 | 0.75 | CA12 (0.32) | MMP1MMP2CA12CA1CA2 | |
| SCHEMBL18882601 | 0.75 | ALDH1A1 (0.35) | MEN1KMT2AFAAHMAPK1ALDH1A1 | |
| SCHEMBL20711353 | 0.75 | CYP2D6 (0.45) | MEN1KMT2AEPHX1PSMB5MMP1 | |
| SCHEMBL17919017 | 0.75 | — | — | |
| SCHEMBL14417043 | 0.75 | CRBN (0.36) | MEN1KMT2AFAAHMAPK1ALDH1A1 | |
| SCHEMBL13607969 | 0.74 | SMN1; SMN2 (0.47) | MEN1KMT2AFAAHMAPK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453051-B2 | Cyclosporin derivatives | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-09-27 | — | — | US | disclosed |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | LEAD DISCOVER CENTER GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-1686990-B1 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7101902-B2 | 2-guanidinylimidazolidinedione compounds and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | ARMY, UNITED STATES | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | GUCY1B2, GUCY1A2, AGK | MEN1 3074/4885KMT2A 1402/4885FAAH 2060/4885 |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | CHP1, RYR2, CANX | MEN1 2226/4885KMT2A 4606/4885FAAH 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.